AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026310392
Cite this article
1
Download
22
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW ARTICLE

Baxdrostat for uncontrolled and resistant hypertension: Clinical evidence, regulatory approval, and practical implications

Yogi Puji Rachmawan1* ,  Witri Pratiwi2 ,  Bagus Andi Pramono3 ,  Erdiansyah Zulyadaini4 ,  Wella Karolina5,6 ,  Tuko Srimulyo7 ,  Meity Ardiana8,9 ,  Antonia Anna Lukito10
Show Less
1 Department of Cardiovascular Medicine, Faculty of Medicine, Universitas Swadaya Gunung Jati, Cirebon, West Java , Indonesia
2 Department of Community Medicine and Public Health, Faculty of Medicine, Universitas Swadaya Gunung Jati, Cirebon, West Java , Indonesia
3 Department of Internal Medicine, Panembahan Senopati Regional General Hospital, Yogyakarta, Special Region of Yogyakarta , Indonesia
4 Department of Internal Medicine, Soeselo Regional General Hospital, Slawi, Central Java , Indonesia
5 Department of Cardiology and Vascular Medicine, Dr. Saiful Anwar General Academic Hospital, Malang, East Java , Indonesia
6 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java , Indonesia
7 Department of Internal Medicine, Nirmala Suri Hospital, Sukoharjo, Central Java , Indonesia
8 Department of Cardiology and Vascular Medicine, Dr. Soetomo General Academic Hospital, Surabaya, East Java , Indonesia
9 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java , Indonesia
10 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Pelita Harapan, Jakarta , Indonesia
Received: 28 July 2026 | Revised: 8 September 2026 | Accepted: 21 September 2026 | Published online: 16 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Poor blood-pressure control and treatment resistance contribute to cardiovascular and kidney complications. Excess aldosterone offers a therapeutic target.

Objective: This narrative review evaluates the pharmacological profile, clinical efficacy, safety, and regulatory development of baxdrostat, an oral aldosterone synthase inhibitor designed to preserve cortisol production.

Key findings: In BaxHTN, a phase 3 trial in uncontrolled or resistant hypertension, the placebo-adjusted decrease in seated systolic blood pressure at week 12 was 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg; Bax24, a phase 3 ambulatory blood-pressure trial in resistant hypertension, recorded a 14.0 mmHg placebo-adjusted decrease in 24-hour ambulatory systolic pressure with 2 mg. FigHTN, a phase 2 trial in chronic kidney disease, identified a preliminary albuminuria signal, but cardiorenal outcome studies have not yet been completed. The main recognised risks are hyperkalaemia and hyponatraemia, particularly when kidney function is impaired. The United States prescribing information states that safety and effectiveness of initiation at an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2 have not been established, and serum potassium, sodium, and eGFR require surveillance during initiation and dose adjustment. The United States Food and Drug Administration approved baxdrostat (Baxfendy) on May 15, 2026, as an add-on treatment for adults whose hypertension remains inadequately controlled. Concomitant use with a mineralocorticoid receptor antagonist has not been evaluated and should not presently be recommended.

Conclusion: Comparative and long-term outcome evidence is still required, while full efficacy and safety results of the completed phase 3 BaxAsia trial in Asian populations are awaited.

Keywords
Aldosterone synthase inhibitor
Baxdrostat
Blood pressure
CYP11B2
Resistant hypertension
Uncontrolled hypertension
Funding
None.
Conflict of interest
The authors declare they have no competing interests.
References
  1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1
  2. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084
  3. Chan RJ, Helmeczi W, Hiremath SS. Revisiting resistant hypertension: a comprehensive review. Intern Med J. 2023;53(10):1739-1751. doi: 10.1111/imj.16189
  4. Calhoun DA, Booth JN 3rd, Oparil S, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451-458. doi: 10.1161/HYPERTENSIONAHA.113.02026
  5. Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14(1):7-12. doi: 10.1111/j.1751-7176.2011.00556.x
  6. Badan Penelitian dan Pengembangan Kesehatan. Laporan Nasional Riskesdas 2018 [2018 Riskesdas National Report]. Jakarta, Indonesia: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2019. [In Indonesian]. Accessed October 22, 2026. https://repository.kemkes.go.id/book/1323
  7. Hikmayani AA, Rachmawan YP. Profile of hypertensive Indonesian patients in a cardiovascular hospital using ambulatory blood pressure monitoring focused on resistant hypertension. Clin Epidemiol Glob Health. 2024;28:101665. doi: 10.1016/j.cegh.2024.101665
  8. Rachmawan YP, Pratiwi W. Hipertensi resisten: diagnosis dan tatalaksana. J Teras Kesehat. 2025;8(1):51-62. doi: 10.38215/jtkes.v8i1.161
  9. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026
  10. World Health Organization. Guideline for the Pharmacological Treatment of Hypertension in Adults. Geneva, Switzerland: World Health Organization; 2021. Accessed October 22, 2026. https://www.who.int/publications/i/item/9789240033986
  11. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X
  12. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3
  13. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi: 10.1056/NEJMoa2025845
  14. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263. doi: 10.1056/NEJMoa2110956
  15. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-1642. doi: 10.1161/CIRCULATIONAHA.111.068064
  16. Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64(5):1012-1021. doi: 10.1161/HYPERTENSIONAHA.114.03850
  17. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-1080. doi: 10.1161/HYPERTENSIONAHA.111.170308
  18. AstraZeneca. Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension. Published May 18, 2026. Accessed October 22, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/Baxdrostat-MNR-2026.html
  19. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173(1):10-20. doi: 10.7326/M20-0065
  20. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies—a review of the current literature. Horm Metab Res. 2012;44(3):157-162. doi: 10.1055/s-0031-1295438
  21. Cannavo A, Bencivenga L, Liccardo D, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598. doi: 10.1155/2018/1204598
  22. Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2025;110(9):2453-2495. doi: 10.1210/clinem/dgaf284
  23. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9(12):876-892. doi: 10.1016/S2213-8587(21)00210-2
  24. Turcu AF, Yang J, Vaidya A. Primary aldosteronism—a multidimensional syndrome. Nat Rev Endocrinol. 2022;18(11):665-682. doi: 10.1038/s41574-022-00730-2
  25. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480
  26. Flack JM, Azizi M, Brown JM, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393(14):1363-1374. doi: 10.1056/NEJMoa2507109
  27. Flack JM, Azizi M, Brown JM, et al. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025;48(11):2911-2923. doi: 10.1038/s41440-025-02297-7
  28. AstraZeneca Pharmaceuticals LP. Baxfendy (baxdrostat): Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026. Revised May 2026. Accessed October 22, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf
  29. Verma S, Pandey A, Pandey AK, et al. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am J Physiol Heart Circ Physiol. 2024;326(3):H670-H688. doi: 10.1152/ajpheart.00419.2023
  30. Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189-196. doi: 10.1161/HYPERTENSIONAHA.116.07716
  31. Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46(1):108-118. doi: 10.1038/s41440-022-01070-4
  32. Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395-405. doi: 10.1056/NEJMoa2213169
  33. Azizi M, Brown JM, Dwyer JP, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10532):988-999. doi: 10.1016/S0140-6736(25)02549-8
  34. Dwyer JP, Maklad N, Vedin O, et al. Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2026;37(2):299-311. doi: 10.1681/ASN.0000000849
  35. AstraZeneca. Phase III study investigating heart failure and cardiovascular death with baxdrostat in combination with dapagliflozin (PREVENT-HF). ClinicalTrials.gov identifier: NCT06677060. Updated October 21, 2026. Accessed October 22, 2026. https://clinicaltrials.gov/study/NCT06677060
  36. AstraZeneca. A phase III study to investigate the efficacy and safety of baxdrostat in combination with dapagliflozin on CKD progression in participants with CKD and high blood pressure. ClinicalTrials.gov identifier: NCT06268873. Updated June 26, 2026. Accessed October 22, 2026. https://clinicaltrials.gov/study/NCT06268873
  37. Kumbhani DJ. Efficacy and safety of baxdrostat in patients with uncontrolled hypertension—HALO. American College of Cardiology. Published March 4, 2023. Accessed October 22, 2026. https://www.acc.org/latest-in-cardiology/clinical-trials/2023/03/01/23/34/halo
  38. de Jager RL, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84(1):18-24. doi: 10.1111/bcp.13402
  39. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302. doi: 10.1097/HJH.0000000000002843
  40. AstraZeneca. A study to investigate the efficacy and safety of baxdrostat in participants with uncontrolled hypertension on two or more medications including participants with resistant hypertension. ClinicalTrials.gov identifier: NCT06344104. Updated April 21, 2026. Accessed October 22, 2026. https://clinicaltrials.gov/study/NCT06344104
  41. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018
  42. Cheung AK, Chang TI, Cushman WC, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. doi: 10.1016/j.kint.2020.11.003
  43. Burton JO, Coats AJS, Kovesdy CP, et al. An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum. Eur J Heart Fail. 2022;24(9):1467-1477. doi: 10.1002/ejhf.2612
  44. AstraZeneca. Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension. Published December 2, 2025. Accessed October 22, 2026. https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension.html
  45. US Food and Drug Administration. Baxfendy (baxdrostat) Tablets: NDA 219878 Approval Letter. Silver Spring, MD: US Food and Drug Administration; 2026. Published May 15, 2026. Accessed October 22, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/219878Orig1s000Approv.pdf
  46. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi: 10.1093/eurheartj/ehae178
  47. Yusuf IA, Badero OJ, Ihesiulo A, Okwah MN, Oshodin A, Asikong E. Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: a phenotype-stratified systematic review and network meta-analysis of randomized trials. PLoS ONE. 2026;21(6):e0349932. doi: 10.1371/journal.pone.0349932
  48. Mohamed KA, Elshabrawi MN, Mohammed HA, et al. Dose-response relationships and comparative efficacy of aldosterone synthase inhibitors in resistant hypertension: a comprehensive network meta-analysis and meta-regression. J Clin Med. 2026;15(12):4477. doi: 10.3390/jcm15124477
  49. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7
  50. US Food and Drug Administration. Drug Trials Snapshots: Tryvio. Approval date March 19, 2024. Accessed October 22, 2026. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tryvio
  51. Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ. 2024;385:e079108. doi: 10.1136/bmj-2023-079108
  52. Laffin LJ, Rodman D, Luther JM, et al. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial. JAMA. 2023;330(12):1140-1150. doi: 10.1001/jama.2023.16029
  53. Laffin LJ, Kopjar B, Melgaard C, et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392(18):1813-1823. doi: 10.1056/NEJMoa2501440
  54. Saxena M, Laffin L, Borghi C, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA. 2025;334(5):409-418. doi: 10.1001/jama.2025.9413
  55. Kandzari DE, Townsend RR, Kario K, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809-1823. doi: 10.1016/j.jacc.2023.08.045
  56. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476-2486. doi: 10.1016/S0140-6736(21)00788-1
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing